TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00571259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin 1000U/mL
Description: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
Study: NCT00571259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Sodium Citrate with Gentamicin 320 mcg/mL
Description: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
Study: NCT03153163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
Study: NCT01554696

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: oral
Study: NCT02915549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Feeding without MEF
Description: This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Feeding with MEF
Description: This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
Study: NCT04174729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: handgrip strength
Description: First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
Study: NCT01554696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: oral
Study: NCT04174729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door handle device
Description: To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tap device
Description: To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door pull handle
Description: To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linear Switch device
Description: To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
Study: NCT04174729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door Key device
Description: To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
Study: NCT01554696

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: oral
Study: NCT00887900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK)
Description: Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penetrated keratoplasty
Description: Regular corneal transplant using the penetrated keratoplasty technique
Study: NCT02707614

Intervention type: PROCEDURE
Intervention: Robotic vs open prostastectomy
Description: robotic minimal invasive surgery
Study: NCT03256552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium MDI 28.8 micrograms
Description: Glycopyrronium MDI 28.8 micrograms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium MDI 14.4 micrograms
Description: Glycopyrronium MDI 14.4 micrograms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium MDI 7.2 micrograms
Description: Glycopyrronium MDI 7.2 micrograms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo Inhalation Aerosol
Study: NCT03272594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Description: Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24% oral sucrose
Description: Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
Study: NCT00003217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT03056456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)
Study: NCT00003217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT01670357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6034 3%
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6034 5%
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-6034 Placebo
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Study: NCT03289728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)
Description: Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with \< moderate ischemia will receive medical treatment only (MT).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cornorary angioplasty
Description: Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
Study: NCT00973791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
Study: NCT03277846

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nexalin Based Trans-Cranial Electrical Stimulation
Description: The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexalin Based Trans-Cranial Electrical Stimulation
Description: The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nexalin Based Trans-Cranial Electrical Stimulation
Description: The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexalin Based Trans-Cranial Electrical Stimulation
Description: The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
Study: NCT03638817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count
Study: NCT03056456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (Humalog)
Description: Administered SC
Study: NCT02647632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study: NCT01888497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 250 mg, oral, prior to bedtime on the night before performance testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine citrate
Description: 76 mg, oral, prior to bedtime on the night before performance testing
Study: NCT02647632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study: NCT01051076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VWF/FVIII concentrates
Description: 200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
Study: NCT04912973

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotically Assisted Total Knee Arthroplasty - Knee Replacement
Description: Robotically Assisted Total Knee Arthroplasty with a particular alignment strategy
Study: NCT01888497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triazolam
Description: 0.5 mg, oral, prior to bedtime on the night before performance testing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, prior to bedtime on the night before performance testing
Study: NCT01598116

Intervention type: PROCEDURE
Intervention: Urine collection and ultrasonography
Description: Bagged urine collection and ultrasound at each visit

Intervention type: PROCEDURE
Intervention: Urine collection
Description: Bagged urine collection
Study: NCT03240575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Fixed Dose Combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: Fixed Dose Combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fixed Dose Combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Fixed Dose Combination
Study: NCT00827411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel / Prasugrel
Description: modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VerifyNow
Description: point of care assay VerifyNow (ACCUMETRICS San Diego USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and clopidogrel / Prasugrel
Description: aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel / Prasugrel
Description: maintenance dose of clopidogrel / Prasugrel and aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Interruption of clopidogrel / Prasugrel after one year of follow-up
Study: NCT02208791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study: NCT00228891

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Effect of Pulsatile IV insulin on diabetic neuropathy
Description: Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effect of Pulsatile IV Insulin on diabetic neuropathy
Description: Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
Study: NCT01368575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: CABG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG combined with MV repair with remodeling annuloplasty rigid ring
Description: CABG combined with MV repair with remodeling annuloplasty rigid ring
Study: NCT03780452

Intervention type: DEVICE
Intervention: novel dynamic compression intramedullary nail
Description: Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
Study: NCT01249625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N95 Respirator
Description: Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical/surgical mask
Description: Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
Study: NCT05058027

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GUARDIX-SG®
Description: GUARDIX-SG® 6g prefilled syringe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Medicurtain® 5ml prefilled syringe
Study: NCT02249975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2 CryoBalloon Focal Ablation System
Description: The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.~Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.~Evaluations include, but are not limited to the following:~* Device malfunctions~* Adverse events~* Patient Pain~* Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus.
Study: NCT01200693

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus eluting stent
Description: Implantation of Sirolimus eluting stent
Study: NCT01368575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG combined with MV repair with remodeling annuloplasty rigid ring
Description: CABG combined with MV repair with remodeling annuloplasty rigid ring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus
Description: CABG combined with MV repair with remodeling annuloplasty
Study: NCT01200693

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: Implantation of Everolimus eluting stent
Study: NCT01368575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG and MV replacement
Description: coronary artery bypass grafting and mitral valve replacement
Study: NCT02595736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SC)
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200327 (SC)
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200327 (IV)
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (IV)
Description: Administered IV
Study: NCT01081808

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EGFRBi-armed autologous activated T cells
Description: EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
Study: NCT03938116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healing Hearts Together
Description: Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
Study: NCT01394575

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT with an simultaneous integrated boost
Description: IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
Study: NCT02306980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colostrum
Description: Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
Study: NCT01815281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot Mechanical Stimulation (GONDOLA)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Foot Mechanical Stimulation (GONDOLA)
Study: NCT04535284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching.
Study: NCT01320683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT02159547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: 50 mg intravenous arveles in 50 ml saline in 5 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 50 ml normal saline
Study: NCT00200226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: misoprostol 400mcg 12 hrs prior to procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin B6
Description: Vitamin B6 50 mg orally 12 hrs prior to procedure
Study: NCT01816464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe.
Study: NCT01947400

Intervention type: OTHER
Intervention: Hospitalists
Description: AIDET Training
Study: NCT04054037

Intervention type: OTHER
Intervention: No intervention
Description: This is an observation study, no intervention will be indicated during diagnosis and treatment.